Evaluation of activity of recombinant lysostaphin against isolates of meticillin-resistant Staphylococcus aureus from Indian hospitals

References

1. Browder H. P., Zygmunt W. A., Young J. R., Tavormina P. A. 1965; Lysostaphin: enzymatic mode of action. Biochem Biophys Res Commun 19:383–389 [View Article][PubMed]
   [Google Scholar]
2. Christensen G. D., Simpson W. A., Younger J. J., Baddour L. M., Barrett F. F., Melton D. M., Beachey E. H. 1985; Adherence of coagulase-negative staphylococci to plastic tissue culture plates: a quantitative model for the adherence of staphylococci to medical devices. J Clin Microbiol 22:996–1006[PubMed]
   [Google Scholar]
3. CLSI 1999; Methods for Determining Bactericidal Activity of Antimicrobial Agents; Approved Guideline. M26-A. Wayne, PA: Clinical and Laboratory Standards Institute;
   [Google Scholar]
4. CLSI 2009a; Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard, 10th edn. M02-A10. Wayne, PA: Clinical and Laboratory Standards Institute;
   [Google Scholar]
5. CLSI 2009b; Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard, 8th edn. M07-A8. Wayne, PA: Clinical and Laboratory Standards Institute;
   [Google Scholar]
6. Dajcs J. J., Hume E. B., Moreau J. M., Caballero A. R., Cannon B. M., O’Callaghan R. J. 2000; Lysostaphin treatment of methicillin-resistant Staphylococcus aureus keratitis in the rabbit. Invest Ophthalmol Vis Sci 41:1432–1437[PubMed]
   [Google Scholar]
7. Hill R. L. R., Kearns A. M., Nash J., North S. E., Pike R., Newson T., Woodford N., Calver R., Livermore D. M. 2010; Linezolid-resistant ST36 methicillin-resistant Staphylococcus aureus associated with prolonged linezolid treatment in two paediatric cystic fibrosis patients. J Antimicrob Chemother 65:442–445 [View Article][PubMed]
   [Google Scholar]
8. Jones J. C., Rogers T. J., Brookmeyer P., Dunne W. M. Jr, Storch G. A., Coopersmith C. M., Fraser V. J., Warren D. K. 2007; Mupirocin resistance in patients colonized with methicillin-resistant Staphylococcus aureus in a surgical intensive care unit. Clin Infect Dis 45:541–547 [View Article][PubMed]
   [Google Scholar]
9. Khatri G. S., Sharma R. 2005; Expression of recombinant matures lysostaphin. US Patent 6,897,041 B1.
10. Kokai-Kun J. F., Walsh S. M., Chanturiya T., Mond J. J. 2003; Lysostaphin cream eradicates Staphylococcus aureus nasal colonization in a cotton rat model. Antimicrob Agents Chemother 47:1589–1597 [View Article][PubMed]
    [Google Scholar]
11. Mangili A., Bica I., Snydman D. R., Hamer D. H. 2005; Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 40:1058–1060 [View Article][PubMed]
    [Google Scholar]
12. McCoy M. 2004; Killing staph together: start-up Biosynexus places fermentation project at newly started Avecia facility. Chem Eng News 82:36–40
    [Google Scholar]
13. Mirza Z. M., Kumar A., Kalia N. P., Zargar A., Khan I. A. 2011; Piperine as an inhibitor of the MdeA efflux pump of Staphylococcus aureus. J Med Microbiol 60:1472–1478 [View Article][PubMed]
    [Google Scholar]
14. Patron R. L., Climo M. W., Goldstein B. P., Archer G. L. 1999; Lysostaphin treatment of experimental aortic valve endocarditis caused by a Staphylococcus aureus isolate with reduced susceptibility to vancomycin. Antimicrob Agents Chemother 43:1754–1755[PubMed]
    [Google Scholar]
15. Recsei P. A., Gruss A. D., Novick R. P. 1987; Cloning, sequence, and expression of the lysostaphin gene from Staphylococcus simulans. Proc Natl Acad Sci U S A 84:1127–1131 [View Article][PubMed]
    [Google Scholar]
16. Schindler C. A., Schuhardt V. T. 1964; Lysostaphin: a new bacteriolytic agent for the staphylococcus. Proc Natl Acad Sci U S A 51:414–421 [View Article][PubMed]
    [Google Scholar]
17. von Eiff C., Kokai-Kun J. F., Becker K., Peters G. 2003; In vitro activity of recombinant lysostaphin against Staphylococcus aureus isolates from anterior nares and blood. Antimicrob Agents Chemother 47:3613–3615 [View Article][PubMed]
    [Google Scholar]
18. Walencka E., Sadowska B., Rozalska S., Hryniewicz W., Rózalska B. 2005; Lysostaphin as a potential therapeutic agent for staphylococcal biofilm eradication. Pol J Microbiol 54:191–200[PubMed]
    [Google Scholar]
19. Yang X. Y., Li C. R., Lou R. H., Wang Y. M., Zhang W. X., Chen H. Z., Huang Q. S., Han Y. X., Jiang J. D., You X. F. 2007; In vitro activity of recombinant lysostaphin against Staphylococcus aureus isolates from hospitals in Beijing, China. J Med Microbiol 56:71–76 [View Article][PubMed]
    [Google Scholar]